ArticleVirology journal2012
Anti-infectivity of camel polyclonal antibodies against hepatitis C virus in Huh7.5 hepatoma.
Article in Virology journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Camel hump oil and milk vs. plant-based oils in aging-related oxidative stress and inflammation: a systematic review and meta-analysis.Frontiers in nutrition · 2025Pooled it
- Impact of urea as a protein substitute in growing camel rations on performance, nitrogen balance, blood metabolites, immune status, and rumen fermentation.Open veterinary journal · 2025Article
- Detection of viral antibodies in camel sera using magnetic particle spectroscopy.Applied microbiology and biotechnology · 2023Article
- Article
- Camel milk protectiveness toward multiple liver disorders: A review.Frontiers in nutrition · 2022Review
- Postbiotic Gamma-Aminobutyric Acid and Camel Milk Intervention as Innovative Trends Against Hyperglycemia and Hyperlipidemia in Streptozotocin-Induced CFrontiers in microbiology · 2022Article
- Research Development on Anti-Microbial and Antioxidant Properties of Camel Milk and Its Role as an Anti-Cancer and Anti-Hepatitis Agent.Antioxidants (Basel, Switzerland) · 2021Review
- Nutritional, antimicrobial and medicinal properties of Camel's milk: A review.Saudi journal of biological sciences · 2021Review
- Article
- Bacteriostatic and Bactericidal Activities of Camel Lactoferrins Against Salmonella enterica Serovar Typhi.Probiotics and antimicrobial proteins · 2020Article
- Synergistic Killing of Pathogenic Escherichia coli Using Camel Lactoferrin from Different Saudi Camel Clans and Various Antibiotics.The protein journal · 2019Article
- Variability of Some Milk-Associated Genes and Proteins in Several Breeds of Saudi Arabian Camels.The protein journal · 2018Article
- Influence of camel milk on the hepatitis C virus burden of infected patients.Experimental and therapeutic medicine · 2017Article
- Why whey? Camel whey protein as a new dietary approach to the management of free radicals and for the treatment of different health disorders.Iranian journal of basic medical sciences · 2017Review
- Screening the anti infectivity potentials of native N- and C-lobes derived from the camel lactoferrin against hepatitis C virus.BMC complementary and alternative medicine · 2014Article
- Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: comparison study.Virology journal · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo extend the study of the camel milk proteins which have antiviral activity against HCV, camel naïve polyclonal IgGs, α-lactalbumin were purified from camel milk and their anti-HCV effect was examined using PBMCs and Huh7.5 cell-lines. They were compared with the activity of human polyclonal IgGs and camel lactoferrin and casein. MATERIAL AND
methodsThree types of experiments were performed on PBMCs and HuH7.5 cell. HCV was directly incubated with the purified proteins and then mixed with both cell types, or the proteins were incubated with the cells and then exposed to HCV, or the HCV pre-infected cells were treated with the proteins to inhibit intracellular replication. The proteins were added to cells or virus at different concentrations and time intervals.
resultsPretreated PBMCs and Huh7.5 cells with milk proteins were not protected when exposed to HCV infection. The direct interaction between HCV and camel IgGs and camel lactoferrin (cLf) led to a complete inhibition of HCV entry into cells, while casein, α-lactalbumin and human IgGs failed to inhibit HCV entry at any tested concentration. Camel IgGs showed ability to recognize HCV peptides with a significant titer (12 × 10(3)) in comparison with human IgGs which failed to do it. Camel lactoferrin was capable of inhibiting the intracellular HCV replication at concentrations of 0.25-1.25 mg/ml.
conclusionCamel milk naïve polyclonal IgGs isolated from camel milk could inhibit the HCV infectivity and demonstrated strong signal against its synthetic peptides. Lactoferrin inhibit the HCV infectivity started from 0.25 mg/ml. However, α-lactalbumin, human IgGs and casein failed to demonstrate any activity against HCV infectivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.